Skip to main content
. 2018 Sep 26;2(12):1479–1492. doi: 10.1002/hep4.1259

Figure 5.

Figure 5

Inhibition of PAI‐1 attenuates HFHS diet‐induced obesity and hepatic steatosis but does not prevent hepatic fibrosis. (A) Plasma level of active PAI‐1 (ng/mL), (B) body weight change (%), (C) H&E‐stained liver sections, (D) steatosis grade, (E) hepatic triglyceride content (mg/g liver), (F) number of inflammatory foci on H&E sections per hpf, (G) plasma ALT (U/L), (H) F4/80‐stained liver sections with quantification (# cells/100 hepatocytes), (I) Masson’s trichrome‐stained liver sections with quantification of trichrome staining, (J) hepatic hydroxyproline content (µg/g protein), and (K) hepatic level of active tPA (ng/g liver) in C57BL/6J mice fed an HFHS diet or SFD with or without TM5441 for 8 weeks or 16 weeks. Values are expressed as mean ± SD; n = 8; *P < 0.05. SFD was statistically different (P < 0.05) than mice fed an HFHS diet for 8 or 16 weeks for all parameters measured.